Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Immunovant, Inc.

Immunovant, Inc. (IMVT) Stock Overview

Explore Immunovant, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IMVT●NASDAQ
HealthcareBiotechnology
$44.37
$0.02(0.05%)
U.S. Market opens in 45h 32m

Immunovant, Inc. (IMVT)

Meyka AI Score

Z

Key Financials

Market Cap9.2B
P/E Ratio-15.65
EPS (TTM)$-2.82
ROE-0.70%
Fundamental Analysis

AI Price Forecasts

1 Month$39.48
3 Months$48.76
1 Year Target$31.91

IMVT Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Immunovant, Inc. (NASDAQ: IMVT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Immunovant, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of IMVT on the NASDAQ shows an RSI of 69.38, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $31.91 for the NASDAQ listing.

Key metrics behind Immunovant, Inc.'s NASDAQ-traded stock include a P/E ratio of -15.65 and a market capitalization of 9.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of IMVT on the NASDAQ.

Price Performance (NASDAQ: IMVT)

1-Day Change
0.05%
5-Day Change
5.24%
1-Month Change
12.24%
3-Month Change
30.003%
6-Month Change
66.80%
Year-to-Date (YTD) Change
74.55%
1-Year Change
198.99%
3-Year Change
115.60%
5-Year Change
433.94%
All-Time (Max) Change
345.93%

Contact Information

https://immunovant.com
917 580 3099
1000 Park Forty Plaza, Durham, NY, 27713

Company Facts

3,150 Employees
IPO DateJun 21, 2019
CountryUS
Actively Trading

Frequently Asked Questions